LISATA THERAPEUTICS, INC.

LISATA THERAPEUTICS, INC. (LSTA) is a publicly listed company on US equity markets.

Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.

The company reports trailing twelve-month revenue of $7.92M and net loss of $4.49M.

Key metrics include a return on equity of -41.1%, a debt-to-equity ratio of 0.31.

Use FINOTAUR to track LSTA's price action, review fundamentals, and stay current with company news — all in one research dashboard.